EPH21 Real-World Evidence of Adverse Kidney Outcomes for Intravitreal Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors Among Patients with Diabetic Retinopathy
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.774
https://www.valueinhealthjournal.com/article/S1098-3015(22)00975-5/fulltext
Title :
EPH21 Real-World Evidence of Adverse Kidney Outcomes for Intravitreal Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors Among Patients with Diabetic Retinopathy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00975-5&doi=10.1016/j.jval.2022.04.774
First page :
Section Title :
Open access? :
No
Section Order :
10703